Becaplermin biosimilar - Virchow Group

Drug Profile

Becaplermin biosimilar - Virchow Group

Alternative Names: Healace; Plermin gel; Recombinant human platelet-derived growth factor-BB gel - Virchow Group

Latest Information Update: 10 Jun 2015

Price : $50

At a glance

  • Originator Virchow Group
  • Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
  • Mechanism of Action Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic foot ulcer

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top